Filing Flows › Akebia Therapeutics (AKBA) › Q3 2026
Akebia Therapeutics (AKBA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Akebia Therapeutics (AKBA) reported revenue of $36.9M for the third quarter 2026 (Q3 2026), -37% from a year earlier and -25% from the quarter before. Operating margin was -31.1%, net loss $14.4M (38.9% of revenue).
Akebia Therapeutics, Q3 2026: revenue $36.9M (-37% year over year), operating margin -31.1%, net loss $14.4M, operating cash flow $2.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $36.9M | -25% | -37% |
| Operating profit | −$11.5M | — | -358% |
| Net earnings | −$14.4M | — | -2758% |
| Operating cash flow | $2.3M | -34% | -92% |
| Free cash flow | $1.6M | -34% | -94% |
What changed
Revenue was $36.9M in Q3 2026, down 37% year over year and down 25% from the previous quarter. Auryxia was the largest line at 54% of revenue. Auryxia lost $22.4M year over year (down 53%), 103% of the total change.
Operating costs exceeded revenue by $11.5M, an operating margin of -31.1%. Total costs fell 11% while revenue fell 37%. The fastest-growing cost line was Other operating costs (+155%). The quarter ended with a net loss of $14.4M, wider than the previous quarter's $8.9M loss.
Operating cash flow was $2.3M (down 92% year over year). Non-cash charges added back $101K of depreciation and $2.8M of share-based compensation. Working capital and other items added $13.8M. Capital expenditures of $706K left free cash flow of $1.6M.
Questions
What was Akebia Therapeutics' revenue in the third quarter 2026?
Akebia Therapeutics (AKBA) reported revenue of $36.9M for the third quarter 2026 (Q3 2026), -37% from a year earlier and -25% from the quarter before.
Was Akebia Therapeutics profitable in the third quarter 2026?
Operating loss was $11.5M (-31.1% of revenue) and net loss $14.4M.